Human Gene FLT1 (ENST00000282397.9_7) from GENCODE V47lift37
  Description: fms related receptor tyrosine kinase 1, transcript variant 1 (from RefSeq NM_002019.4)
Gencode Transcript: ENST00000282397.9_7
Gencode Gene: ENSG00000102755.13_9
Transcript (Including UTRs)
   Position: hg19 chr13:28,874,483-29,069,265 Size: 194,783 Total Exon Count: 30 Strand: -
Coding Region
   Position: hg19 chr13:28,877,304-29,068,980 Size: 191,677 Coding Exon Count: 30 

Page IndexSequence and LinksUniProtKB CommentsPrimersMalaCardsCTD
Gene AllelesRNA-Seq ExpressionMicroarray ExpressionRNA StructureProtein StructureOther Species
GO AnnotationsmRNA DescriptionsPathwaysOther NamesModel InformationMethods
Data last updated at UCSC: 2024-08-22 23:36:26

-  Sequence and Links to Tools and Databases
 
Genomic Sequence (chr13:28,874,483-29,069,265)mRNA (may differ from genome)Protein (1338 aa)
Gene SorterGenome BrowserOther Species FASTAVisiGeneGene interactionsTable Schema
AlphaFoldBioGPSEnsemblEntrez GeneExonPrimerGeneCards
HGNCMalacardsMGIOMIMPubMedReactome
UniProtKBWikipediaBioGrid CRISPR DB

-  Comments and Description Text from UniProtKB
  ID: VGFR1_HUMAN
DESCRIPTION: RecName: Full=Vascular endothelial growth factor receptor 1; Short=VEGFR-1; EC=2.7.10.1; AltName: Full=Fms-like tyrosine kinase 1; Short=FLT-1; AltName: Full=Tyrosine-protein kinase FRT; AltName: Full=Tyrosine-protein kinase receptor FLT; Short=FLT; AltName: Full=Vascular permeability factor receptor; Flags: Precursor;
FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts (in vitro). Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Likewise, isoforms lacking a transmembrane domain, such as isoform 2, isoform 3 and isoform 4, may function as decoy receptors for VEGFA. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates SRC and YES1, and may also phosphorylate CBL. Isoform 1 phosphorylates PLCG. Promotes phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of PTK2/FAK1. Isoform 7 has a truncated kinase domain; it increases phosphorylation of SRC at 'Tyr-418' by unknown means and promotes tumor cell invasion.
CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.
ENZYME REGULATION: Present in an inactive conformation in the absence of bound ligand. Binding of VEGFA, VEGFB or PGF leads to dimerization and activation by autophosphorylation on tyrosine residues.
SUBUNIT: Interacts with VEGFA, VEGFB and PGF. Monomer in the absence of bound VEGFA, VEGFB or PGF. Homodimer in the presence of bound VEGFA, VEGFB and PGF. Can also form a heterodimer with KDR. Interacts (when tyrosine phosphorylated) with CBL, CRK, GRB2, NCK1, PIK3R1, PLCG, PSEN1 and PTPN11. Probably interacts also with PTPRB. Interacts with GNB2L1/RACK1. Identified in a complex with CBL and CD2AP.
INTERACTION: P15692:VEGFA; NbExp=2; IntAct=EBI-1026718, EBI-1026643;
SUBCELLULAR LOCATION: Isoform 1: Cell membrane; Single-pass type I membrane protein. Endosome. Note=Autophosphorylation promotes ubiquitination and endocytosis.
SUBCELLULAR LOCATION: Isoform 2: Secreted.
SUBCELLULAR LOCATION: Isoform 3: Secreted.
SUBCELLULAR LOCATION: Isoform 4: Secreted.
SUBCELLULAR LOCATION: Isoform 5: Cytoplasm (Potential).
SUBCELLULAR LOCATION: Isoform 6: Cytoplasm (Potential).
SUBCELLULAR LOCATION: Isoform 7: Cytoplasm (Potential).
TISSUE SPECIFICITY: Detected in normal lung, but also in placenta, liver, kidney, heart and brain tissues. Specifically expressed in most of the vascular endothelial cells, and also expressed in peripheral blood monocytes. Isoform 2 is strongly expressed in placenta. Isoform 3 is expressed in corneal epithelial cells (at protein level). Isoform 3 is expressed in vascular smooth muscle cells (VSMC).
INDUCTION: Up-regulated in coculture of VSMC/endothelial cell (EC) or by direct exposure to VEGF of VSMC monoculture. Up-regulated from the second trimester of pregnancy to the term and in the placenta of women with preeclampsia (PE). Up-regulated in monocytes exposed to bacterial lipopolysaccharide (LPS).
DOMAIN: The second and third Ig-like C2-type (immunoglobulin-like) domains are sufficient for VEGFA binding.
PTM: N-glycosylated.
PTM: Ubiquitinated after VEGFA-mediated autophosphorylation, leading to proteolytic degradation.
PTM: Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation at Tyr-1169 is important for interaction with PLCG. Phosphorylation at Tyr-1213 is important for interaction with PIK3R1, PTPN11, GRB2, and PLCG. Phosphorylation at Tyr-1333 is important for endocytosis and for interaction with CBL, NCK1 and CRK. Is probably dephosphorylated by PTPRB.
DISEASE: Note=Can contribute to cancer cell survival, proliferation, migration, and invasion, and tumor angiogenesis and metastasis. May contribute to cancer pathogenesis by promoting inflammatory responses and recruitment of tumor-infiltrating macrophages.
DISEASE: Note=Abnormally high expression of soluble isoforms (isoform 2, isoform 3 or isoform 4) may be a cause of preeclampsia.
SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
SIMILARITY: Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
SIMILARITY: Contains 1 protein kinase domain.

-  Primer design for this transcript
 

Primer3Plus can design qPCR Primers that straddle exon-exon-junctions, which amplify only cDNA, not genomic DNA.
Click here to load the transcript sequence and exon structure into Primer3Plus

Exonprimer can design one pair of Sanger sequencing primers around every exon, located in non-genic sequence.
Click here to open Exonprimer with this transcript

To design primers for a non-coding sequence, zoom to a region of interest and select from the drop-down menu: View > In External Tools > Primer3


-  MalaCards Disease Associations
  MalaCards Gene Search: FLT1
Diseases sorted by gene-association score: anal canal squamous cell carcinoma (22), eclampsia (19), pre-eclampsia (19), twin-to-twin transfusion syndrome (16), corneal neovascularization (15), bronchopulmonary dysplasia (15), placental insufficiency (15), angiosarcoma (13), placenta accreta (9), angiokeratoma circumscriptum (8), cancer-associated retinopathy (8), placental abruption (7), intracranial structure hemangioma (7), brain angioma (7), cerebral angioma (7), preeclampsia/eclampsia 1 (7), vascular cancer (7), chorioamnionitis (7), glomeruloid hemangioma (7), microvascular complications of diabetes 5 (7), epithelioid hemangioendothelioma (6), mild pre-eclampsia (6), peripartum cardiomyopathy (6), microcystic meningioma (6), lipodermatosclerosis (6), acute mountain sickness (5), microvascular complications of diabetes 1 (5), hellp syndrome (5), interstitial emphysema (5), exudative vitreoretinopathy 1 (4), acute hemorrhagic leukoencephalitis (4), lipid pneumonia (4), retinal vascular disease (4), colorectal cancer (3), rheumatoid arthritis (3), lung cancer (3), breast cancer (3), eye disease (2), pulmonary hypertension (2), renal cell carcinoma (2), macular degeneration, age-related, 1 (2), thyroid cancer, nonmedullary, 2 (1)

-  Comparative Toxicogenomics Database (CTD)
  The following chemicals interact with this gene
  • D013749 Tetrachlorodibenzodioxin
  • D010100 Oxygen
  • D010705 Phosgene
  • D015032 Zinc
  • C006780 bisphenol A
  • C059514 resveratrol
  • C548651 2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester
  • C477639 3-(5-methyl-2-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-yl)propionic acid
  • C010643 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
  • C121707 7,3'-dihydroxy-4'-methoxyisoflavone
          more ... click here to view the complete list

+  Common Gene Haplotype Alleles
  Press "+" in the title bar above to open this section.

-  RNA-Seq Expression Data from GTEx (53 Tissues, 570 Donors)
  Highest median expression: 19.50 RPKM in Thyroid
Total median expression: 256.12 RPKM



View in GTEx track of Genome Browser    View at GTEx portal     View GTEx Body Map

+  Microarray Expression Data
  Press "+" in the title bar above to open this section.

-  mRNA Secondary Structure of 3' and 5' UTRs
 
RegionFold EnergyBasesEnergy/Base
Display As
5' UTR -153.30285-0.538 Picture PostScript Text
3' UTR -768.502821-0.272 Picture PostScript Text

The RNAfold program from the Vienna RNA Package is used to perform the secondary structure predictions and folding calculations. The estimated folding energy is in kcal/mol. The more negative the energy, the more secondary structure the RNA is likely to have.

-  Protein Domain and Structure Information
  InterPro Domains: Graphical view of domain structure
IPR007110 - Ig-like
IPR013783 - Ig-like_fold
IPR013098 - Ig_I-set
IPR003599 - Ig_sub
IPR003598 - Ig_sub2
IPR011009 - Kinase-like_dom
IPR000719 - Prot_kinase_cat_dom
IPR017441 - Protein_kinase_ATP_BS
IPR001245 - Ser-Thr/Tyr_kinase_cat_dom
IPR008266 - Tyr_kinase_AS
IPR020635 - Tyr_kinase_cat_dom
IPR001824 - Tyr_kinase_rcpt_3_CS
IPR009135 - Tyr_kinase_VEGFR1_rcpt_N
IPR009134 - Tyr_kinase_VEGFR_rcpt_N

Pfam Domains:
PF00047 - Immunoglobulin domain
PF00069 - Protein kinase domain
PF07679 - Immunoglobulin I-set domain
PF07686 - Immunoglobulin V-set domain
PF07714 - Protein tyrosine and serine/threonine kinase
PF13895 - Immunoglobulin domain
PF13927 - Immunoglobulin domain
PF17988 - VEGFR-2 Transmembrane domain

SCOP Domains:
48726 - Immunoglobulin
49401 - Bacterial adhesins
56112 - Protein kinase-like (PK-like)

Protein Data Bank (PDB) 3-D Structure
MuPIT help
1FLT - X-ray MuPIT 1QSV - NMR MuPIT 1QSZ - NMR MuPIT 1QTY - X-ray MuPIT 1RV6 - X-ray MuPIT 2XAC - X-ray MuPIT 3HNG - X-ray MuPIT


ModBase Predicted Comparative 3D Structure on P17948
FrontTopSide
The pictures above may be empty if there is no ModBase structure for the protein. The ModBase structure frequently covers just a fragment of the protein. You may be asked to log onto ModBase the first time you click on the pictures. It is simplest after logging in to just click on the picture again to get to the specific info on that model.

-  Orthologous Genes in Other Species
  Orthologies between human, mouse, and rat are computed by taking the best BLASTP hit, and filtering out non-syntenic hits. For more distant species reciprocal-best BLASTP hits are used. Note that the absence of an ortholog in the table below may reflect incomplete annotations in the other species rather than a true absence of the orthologous gene.
MouseRatZebrafishD. melanogasterC. elegansS. cerevisiae
No orthologNo orthologNo orthologNo orthologNo orthologNo ortholog
Gene DetailsGene Details Gene Details  
Gene SorterGene Sorter Gene Sorter  
 RGDEnsembl   
      
      

-  Gene Ontology (GO) Annotations with Structured Vocabulary
  Molecular Function:
GO:0000166 nucleotide binding
GO:0004672 protein kinase activity
GO:0004713 protein tyrosine kinase activity
GO:0004714 transmembrane receptor protein tyrosine kinase activity
GO:0005021 vascular endothelial growth factor-activated receptor activity
GO:0005515 protein binding
GO:0005524 ATP binding
GO:0016301 kinase activity
GO:0016740 transferase activity
GO:0019838 growth factor binding
GO:0036326 VEGF-A-activated receptor activity
GO:0036327 VEGF-B-activated receptor activity
GO:0036332 placental growth factor-activated receptor activity

Biological Process:
GO:0001525 angiogenesis
GO:0002548 monocyte chemotaxis
GO:0006468 protein phosphorylation
GO:0006935 chemotaxis
GO:0007169 transmembrane receptor protein tyrosine kinase signaling pathway
GO:0007275 multicellular organism development
GO:0008284 positive regulation of cell proliferation
GO:0010863 positive regulation of phospholipase C activity
GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling
GO:0016310 phosphorylation
GO:0016477 cell migration
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0030154 cell differentiation
GO:0030335 positive regulation of cell migration
GO:0030949 positive regulation of vascular endothelial growth factor receptor signaling pathway
GO:0035924 cellular response to vascular endothelial growth factor stimulus
GO:0036323 vascular endothelial growth factor receptor-1 signaling pathway
GO:0038084 vascular endothelial growth factor signaling pathway
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043552 positive regulation of phosphatidylinositol 3-kinase activity
GO:0045766 positive regulation of angiogenesis
GO:0046777 protein autophosphorylation
GO:0048010 vascular endothelial growth factor receptor signaling pathway
GO:0048514 blood vessel morphogenesis
GO:0048598 embryonic morphogenesis
GO:1905563 negative regulation of vascular endothelial cell proliferation

Cellular Component:
GO:0005576 extracellular region
GO:0005615 extracellular space
GO:0005737 cytoplasm
GO:0005768 endosome
GO:0005886 plasma membrane
GO:0005887 integral component of plasma membrane
GO:0005925 focal adhesion
GO:0015629 actin cytoskeleton
GO:0016020 membrane
GO:0016021 integral component of membrane
GO:0043235 receptor complex


-  Descriptions from all associated GenBank mRNAs
  LQ882906 - Sequence 55 from Patent WO2018160841.
X51602 - Human flt mRNA for receptor-related tyrosine kinase.
AF063657 - Homo sapiens vascular endothelial growth factor receptor (FLT1) mRNA, complete cds.
AB385191 - Synthetic construct DNA, clone: pF1KB9075, Homo sapiens FLT1 gene for vascular endothelial growth factor receptor 1 precursor, complete cds, without stop codon, in Flexi system.
EU360600 - Homo sapiens psVEGFR1p mRNA, complete cds.
EU368830 - Homo sapiens soluble VEGF receptor 1-14 (FLT1) mRNA, complete cds.
LQ487916 - Sequence 25 from Patent WO2016083623.
AK300392 - Homo sapiens cDNA FLJ60350 complete cds, highly similar to Vascular endothelial growth factor receptor 1precursor (EC 2.7.10.1).
AK309901 - Homo sapiens cDNA, FLJ99942.
U01134 - Human soluble vascular endothelial cell growth factor receptor (sflt) mRNA, complete cds.
AK292936 - Homo sapiens cDNA FLJ76691 complete cds, highly similar to Homo sapiens fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor), mRNA.
BC039007 - Homo sapiens fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor), mRNA (cDNA clone MGC:47768 IMAGE:5722772), complete cds.
KJ891186 - Synthetic construct Homo sapiens clone ccsbBroadEn_00580 FLT1 gene, encodes complete protein.
KR712039 - Synthetic construct Homo sapiens clone CCSBHm_00034991 FLT1 (FLT1) mRNA, encodes complete protein.
S77812 - flt=vascular endothelial growth factor receptor/VEGF receptor/cell surface tyrosine kinase {clone FLT14} [human, ovarian carcinoma ascitic cells, mRNA Partial Mutant, 338 nt].
S77814 - flt=vascular endothelial growth factor receptor/VEGF receptor/cell surface tyrosine kinase {clone FLT15} [human, ovarian carcinoma ascitic cells, mRNA Partial Mutant, 358 nt].
MP584556 - Sequence 55 from Patent WO2020081767.
JD087294 - Sequence 68318 from Patent EP1572962.
JD038925 - Sequence 19949 from Patent EP1572962.
JD284177 - Sequence 265201 from Patent EP1572962.
JD119806 - Sequence 100830 from Patent EP1572962.
JD041081 - Sequence 22105 from Patent EP1572962.
JD051646 - Sequence 32670 from Patent EP1572962.
JD040303 - Sequence 21327 from Patent EP1572962.
JD168836 - Sequence 149860 from Patent EP1572962.
JD528335 - Sequence 509359 from Patent EP1572962.
JD320161 - Sequence 301185 from Patent EP1572962.
JD329281 - Sequence 310305 from Patent EP1572962.
JD314625 - Sequence 295649 from Patent EP1572962.
JD508274 - Sequence 489298 from Patent EP1572962.
JD043550 - Sequence 24574 from Patent EP1572962.
JD101268 - Sequence 82292 from Patent EP1572962.
JD173992 - Sequence 155016 from Patent EP1572962.
JD241255 - Sequence 222279 from Patent EP1572962.
JD203349 - Sequence 184373 from Patent EP1572962.
JD278725 - Sequence 259749 from Patent EP1572962.
JD262234 - Sequence 243258 from Patent EP1572962.
JD359330 - Sequence 340354 from Patent EP1572962.
JD048651 - Sequence 29675 from Patent EP1572962.
JD404138 - Sequence 385162 from Patent EP1572962.
JD215063 - Sequence 196087 from Patent EP1572962.
JD363557 - Sequence 344581 from Patent EP1572962.
JD040679 - Sequence 21703 from Patent EP1572962.
JD524076 - Sequence 505100 from Patent EP1572962.
JD345094 - Sequence 326118 from Patent EP1572962.
JD565591 - Sequence 546615 from Patent EP1572962.
JD347088 - Sequence 328112 from Patent EP1572962.
JD270240 - Sequence 251264 from Patent EP1572962.
JD217971 - Sequence 198995 from Patent EP1572962.
JD134077 - Sequence 115101 from Patent EP1572962.
JD060678 - Sequence 41702 from Patent EP1572962.
JD439260 - Sequence 420284 from Patent EP1572962.
JD515352 - Sequence 496376 from Patent EP1572962.
AB209050 - Homo sapiens mRNA for fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) variant protein.
JD382724 - Sequence 363748 from Patent EP1572962.
JD433343 - Sequence 414367 from Patent EP1572962.
JF509745 - Homo sapiens p28FLT1 (FLT1) mRNA, complete cds, alternatively spliced.
JF509744 - Homo sapiens p19FLT1 (FLT1) mRNA, complete cds, alternatively spliced.
EF491869 - Homo sapiens intracellular domain VEGFR1 variant 21 mRNA, complete cds, alternatively spliced.
EF491870 - Homo sapiens intracellular domain VEGFR1 variant 21 mRNA, complete cds, alternatively spliced.
EF491868 - Homo sapiens intrecellular domain VEGFR1 variant 18 mRNA, complete cds.
DQ836394 - Homo sapiens idVEGFR-1 (FLT1) mRNA, complete cds.
DQ836395 - Homo sapiens N2idVEGFR-1 (FLT1) mRNA, complete cds.
DQ836396 - Homo sapiens tVEGFR-1 (FLT1) mRNA, partial cds.
EU443152 - Homo sapiens soluble FLT1 variant e15a (FLT1) mRNA, partial cds, alternatively spliced.
AF339822 - Homo sapiens clone IMAGE:451939, mRNA sequence.
LQ650717 - Sequence 64 from Patent WO2016161378.
LQ650836 - Sequence 183 from Patent WO2016161378.
LQ654986 - Sequence 81 from Patent WO2016161388.
MA410039 - JP 2018517429-A/81: FULLY STABILIZED ASYMMETRIC SIRNA.
EU826561 - Homo sapiens soluble VEGFR1 variant 21 (VEGFR1) mRNA, complete cds, alternatively spliced.
LQ650894 - Sequence 241 from Patent WO2016161378.
LQ655044 - Sequence 139 from Patent WO2016161388.
LQ650835 - Sequence 182 from Patent WO2016161378.
LQ654985 - Sequence 80 from Patent WO2016161388.
LQ650893 - Sequence 240 from Patent WO2016161378.
LQ655043 - Sequence 138 from Patent WO2016161388.
LQ650892 - Sequence 239 from Patent WO2016161378.
LQ655042 - Sequence 137 from Patent WO2016161388.
LQ650891 - Sequence 238 from Patent WO2016161378.
LQ655041 - Sequence 136 from Patent WO2016161388.
LQ650834 - Sequence 181 from Patent WO2016161378.
LQ654984 - Sequence 79 from Patent WO2016161388.
LQ650833 - Sequence 180 from Patent WO2016161378.
LQ654983 - Sequence 78 from Patent WO2016161388.
LQ650832 - Sequence 179 from Patent WO2016161378.
LQ654982 - Sequence 77 from Patent WO2016161388.
LQ650889 - Sequence 236 from Patent WO2016161378.
LQ655039 - Sequence 134 from Patent WO2016161388.
LQ650888 - Sequence 235 from Patent WO2016161378.
LQ655038 - Sequence 133 from Patent WO2016161388.
LQ650830 - Sequence 177 from Patent WO2016161378.
LQ654980 - Sequence 75 from Patent WO2016161388.
LQ650829 - Sequence 176 from Patent WO2016161378.
LQ654979 - Sequence 74 from Patent WO2016161388.
EU826562 - Homo sapiens soluble VEGFR1 variant 2 (VEGFR1) mRNA, complete cds, alternatively spliced.
BC029849 - Homo sapiens fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor), mRNA (cDNA clone IMAGE:5176591), with apparent retained intron.
LQ650887 - Sequence 234 from Patent WO2016161378.
LQ655037 - Sequence 132 from Patent WO2016161388.
LQ650828 - Sequence 175 from Patent WO2016161378.
LQ654978 - Sequence 73 from Patent WO2016161388.
LQ650886 - Sequence 233 from Patent WO2016161378.
LQ655036 - Sequence 131 from Patent WO2016161388.
LQ650885 - Sequence 232 from Patent WO2016161378.
LQ655035 - Sequence 130 from Patent WO2016161388.
LQ650827 - Sequence 174 from Patent WO2016161378.
LQ654977 - Sequence 72 from Patent WO2016161388.
LQ650884 - Sequence 231 from Patent WO2016161378.
LQ655034 - Sequence 129 from Patent WO2016161388.
BC046165 - Homo sapiens, clone IMAGE:5192014, mRNA, partial cds.
BC048278 - Homo sapiens, clone IMAGE:5192302, mRNA, partial cds.
LQ650824 - Sequence 171 from Patent WO2016161378.
LQ654974 - Sequence 69 from Patent WO2016161388.
JD444011 - Sequence 425035 from Patent EP1572962.
MA410097 - JP 2018517429-A/139: FULLY STABILIZED ASYMMETRIC SIRNA.
MA410038 - JP 2018517429-A/80: FULLY STABILIZED ASYMMETRIC SIRNA.
MA410096 - JP 2018517429-A/138: FULLY STABILIZED ASYMMETRIC SIRNA.
MA410095 - JP 2018517429-A/137: FULLY STABILIZED ASYMMETRIC SIRNA.
MA410094 - JP 2018517429-A/136: FULLY STABILIZED ASYMMETRIC SIRNA.
MA410037 - JP 2018517429-A/79: FULLY STABILIZED ASYMMETRIC SIRNA.
MA410036 - JP 2018517429-A/78: FULLY STABILIZED ASYMMETRIC SIRNA.
MA410035 - JP 2018517429-A/77: FULLY STABILIZED ASYMMETRIC SIRNA.
MA410092 - JP 2018517429-A/134: FULLY STABILIZED ASYMMETRIC SIRNA.
MA410091 - JP 2018517429-A/133: FULLY STABILIZED ASYMMETRIC SIRNA.
MA410033 - JP 2018517429-A/75: FULLY STABILIZED ASYMMETRIC SIRNA.
MA410032 - JP 2018517429-A/74: FULLY STABILIZED ASYMMETRIC SIRNA.
MA410090 - JP 2018517429-A/132: FULLY STABILIZED ASYMMETRIC SIRNA.
MA410031 - JP 2018517429-A/73: FULLY STABILIZED ASYMMETRIC SIRNA.
MA410089 - JP 2018517429-A/131: FULLY STABILIZED ASYMMETRIC SIRNA.
MA410088 - JP 2018517429-A/130: FULLY STABILIZED ASYMMETRIC SIRNA.
MA410030 - JP 2018517429-A/72: FULLY STABILIZED ASYMMETRIC SIRNA.
MA410087 - JP 2018517429-A/129: FULLY STABILIZED ASYMMETRIC SIRNA.
MA410027 - JP 2018517429-A/69: FULLY STABILIZED ASYMMETRIC SIRNA.

-  Biochemical and Signaling Pathways
  BioCarta from NCI Cancer Genome Anatomy Project
h_no1Pathway - Actions of Nitric Oxide in the Heart
h_vegfPathway - VEGF, Hypoxia, and Angiogenesis

Reactome (by CSHL, EBI, and GO)

Protein P17948 (Reactome details) participates in the following event(s):

R-HSA-194311 VEGFA,B,PLGF bind to VEGFR1 leading to receptor dimerization
R-HSA-195418 NRP-2 associates with VEGFR1 forming complexes on cell surface
R-HSA-195399 VEGF binds to VEGFR leading to receptor dimerization
R-HSA-194306 Neurophilin interactions with VEGF and VEGFR
R-HSA-194313 VEGF ligand-receptor interactions
R-HSA-194138 Signaling by VEGF
R-HSA-9006934 Signaling by Receptor Tyrosine Kinases
R-HSA-162582 Signal Transduction

-  Other Names for This Gene
  Alternate Gene Symbols: A3E342, A3E344, A8KA71, B0LPF1, B2BF46, B2BF47, B2BF48, B3FR89, B5A923, ENST00000282397.1, ENST00000282397.2, ENST00000282397.3, ENST00000282397.4, ENST00000282397.5, ENST00000282397.6, ENST00000282397.7, ENST00000282397.8, F5H5L6, FLT, FRT, NM_002019, O60722, P16057, P17948, Q12954, uc317jzk.1, uc317jzk.2, VEGFR1, VGFR1_HUMAN
UCSC ID: ENST00000282397.9_7
RefSeq Accession: NM_002019.4
Protein: P17948 (aka VGFR1_HUMAN)

-  Gene Model Information
  Click here for a detailed description of the fields of the table above.

-  Methods, Credits, and Use Restrictions
  Click here for details on how this gene model was made and data restrictions if any.